Erytech Pharma is a biopharmaceutical company developing therapies for various forms of cancer and orphan diseases. Utilizing its proprietary ERYCAPS platform, which uses a technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, Co. is developing a pipeline of product candidates for patients with unmet medical needs. Co.'s main product candidate, eryaspase, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. Co. is developing eryaspase for the treatment of cancer, including pancreatic cancer and triple negative breast cancer. The ERYP average annual return since 2017 is shown above.
The Average Annual Return on the ERYP average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ERYP average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ERYP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|